Letter to the Editor: Commentary on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”

Similar Items

• Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
  by: Su Jin Kim, et al.
  Published: (2017-03-01)
• The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
  by: Su Jin Kim, et al.
  Published: (2017-09-01)
• An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin
  by: Yang PS, et al.
  Published: (2018-02-01)
• COMPARISON OF EFFECTIVENESS OF MELOXICAM 15 MG ONLY, COMBINATION OF MELOXICAM 15 MG AND TAMSULOSIN 0.4 MG, AND TAMSULOSIN 0.4 MG ONLY FOR SUCCESS OF TWOC IN BPH PATIENTS WITH FIRST EPISODE OF ACUTE URINARY RETENTION
  by: Muhammad Asro Abdih Yasa, et al.
  Published: (2018-01-01)
• Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial
  by: Shin YS, et al.
  Published: (2016-09-01)